Liu S, Marneth AE, Alexe G, et al. The kinases IKBKE and TBK1 regulate MYC-dependent survival pathways through YB-1 in AML and are targets for therapy. Blood Adv. 2018;2(23):3428-3442. doi:10.1182/bloodadvances.2018016733.

Mandt REK, Lafuente-Monasterio MJ, Sakata-Kato T, et al. In vitro selection predicts malaria parasite resistance to dihydroorotate dehydrogenase inhibitors in a mouse infection model. Sci Transl Med. 2019;11(521). doi:10.1126/scitranslmed.aav1636.

Hacken ET, Valentin R, Regis FFD, et al. Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies. JCI Insight. 2018;3(19). doi:10.1172/jci.insight.121438.

Li Y, Wei L, Meinsohn M-C, et al. A screen of repurposed drugs identifies AMHR2/MISR2 agonists as potential contraceptives. Proc Natl Acad Sci U S A. 2022;119(15):e2122512119. doi:10.1073/pnas.2122512119.

Bellmunt J, Lalani A-KA, Jacobus S, et al. Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma. Br J Cancer. 2018;119(6):707-712. doi:10.1038/s41416-018-0261-0.

Christian S, Merz C, Evans L, et al. The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignancies. Leukemia. 2019;33(10):2403-2415. doi:10.1038/s41375-019-0461-5.

Dardaei L, Wang HQ, Singh M, et al. SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors. Nat Med. 2018;24(4):512-517. doi:10.1038/nm.4497.

Awad MM, Liu S, Rybkin II, et al. Acquired Resistance to KRAS Inhibition in Cancer. N Engl J Med. 2021;384(25):2382-2393. doi:10.1056/NEJMoa2105281.

Sundberg TB, Choi HG, Song J-H, et al. Small-molecule screening identifies inhibition of salt-inducible kinases as a therapeutic strategy to enhance immunoregulatory functions of dendritic cells. Proc Natl Acad Sci U S A. 2014;111(34):12468-73. doi:10.1073/pnas.1412308111.

Kemp MM, Wang Q, Fuller JH, et al. A novel HDAC inhibitor with a hydroxy-pyrimidine scaffold. Bioorg Med Chem Lett. 2011;21(14):4164-9. doi:10.1016/j.bmcl.2011.05.098.